Synairgen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Synairgen's earnings have been declining at an average annual rate of -4.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 105.5% per year.

Anahtar bilgiler

-4.1%

Kazanç büyüme oranı

2.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi11.5%
Gelir büyüme oranı-105.5%
Özkaynak getirisi-72.4%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Aug 24
Here's Why We're Watching Synairgen's (LON:SNG) Cash Burn Situation

Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Apr 29
Is Synairgen (LON:SNG) In A Good Position To Invest In Growth?

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Dec 27
Companies Like Synairgen (LON:SNG) Could Be Quite Risky

We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Sep 13
We're A Little Worried About Synairgen's (LON:SNG) Cash Burn Rate

Companies Like Synairgen (LON:SNG) Could Be Quite Risky

May 31
Companies Like Synairgen (LON:SNG) Could Be Quite Risky

Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Synairgen's (LON:SNG) Cash Burn Situation

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Oct 21
We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

Mar 29
We're Hopeful That Synairgen (LON:SNG) Will Use Its Cash Wisely

How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

Dec 14
How Much Of Synairgen plc (LON:SNG) Do Institutions Own?

Gelir ve Gider Dağılımı

Synairgen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

AIM:SNG Gelir, gider ve kazançlar (GBP Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-736
31 Mar 240-836
31 Dec 230-847
30 Sep 230-947
30 Jun 230-1057
31 Mar 230-14511
31 Dec 220-18515
30 Sep 220-23621
30 Jun 220-28627
31 Mar 220-38540
31 Dec 210-49553
30 Sep 210-46450
30 Jun 210-43448
31 Mar 210-28332
31 Dec 200-14215
30 Sep 200-10211
30 Jun 200-616
31 Mar 200-515
31 Dec 190-413
30 Sep 190-413
30 Jun 190-414
31 Mar 190-313
31 Dec 180-313
30 Sep 183-113
30 Jun 185212
31 Mar 185212
31 Dec 175212
30 Sep 173012
30 Jun 170-312
31 Mar 170-312
31 Dec 160-312
30 Sep 160-312
30 Jun 160-312
31 Mar 160-212
31 Dec 150-211
30 Sep 150-211
30 Jun 150-211
31 Mar 152011
31 Dec 144122
30 Sep 144122
30 Jun 144122
31 Mar 142-112

Kaliteli Kazançlar: SNG is currently unprofitable.

Büyüyen Kar Marjı: SNG is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: SNG is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.

Büyüme Hızlandırma: Unable to compare SNG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: SNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Özkaynak Getirisi

Yüksek ROE: SNG has a negative Return on Equity (-72.4%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin